Home
Global Supplier Directory
APPLIANCE Engineer
Supplier Solutions
APPLIANCE Line
Whitepaper Library
Calendar of Events
Association Locator
Contents Pages
Market Research
Subscription Center


 
Daily News

Boston Scientific Announces 2003 Q4 Results
Feb 3, 2004
 Printable format
 Email this Article
 Search

Medical-device maker Boston Scientific Corp. (Natick, MA, U.S.) has announced its 2003 fourth-quarter results. The company had net income of U.S. $137 million, or $0.16 a share, for the latest quarter, up from $105 million, or $0.12 a share, a year earlier.

The per-share earnings figures reflect a 2-for-1 stock split that took effect in November 2003.

Excluding $4 million in unspecified charges, the company said it would have posted earnings of $141 million, or $0.17 a share, up from $130 million, or $0.15 a share, a year ago.

Analysts surveyed by Thomson First Call were expecting the company to report fourth-quarter earnings, excluding items, of $0.16 a share.

Sales for the latest quarter rose 15 percent to $939 million from $814 million.

International sales jumped 46 percent to $457 million amid a 58 percent surge in European sales. This fourth-quarter surge in profit is being attributed to sales of stents in Europe and other overseas markets. Stents are tiny metal scaffolds used to prop open arteries after they have been unclogged by a procedure known as balloon angioplasty.

In the United States, sales slipped 3.6 percent to $482 million.

In November, Boston Scientific's drug-coated Taxus stent won unanimous backing from a Food and Drug Administration advisory panel, moving it closer to competition with a rival Johnson & Johnson device already on the market.

Taxus and Johnson & Johnson's Cypher are the first of a new generation of the devices that are coated with drugs aimed at preventing arteries from reclogging following angioplasty.

Johnson & Johnson's stent went on sale last April in the United States, where it has gained the bulk of a $2 billion U.S. market. By 2007, analysts estimate the U.S. market for drug-coated stents will rise to about $4.4 billion.

For all of 2003, Boston Scientific had net income of $472 million, or 56 cents a share, up 27 percent from $373 million, or 45 cents a share, in 2002. Sales increased 19 percent to $3.48 billion from $2.92 billion. (AFP)

Back to Daily News

 

Daily News

...........................................................

Jul 29, 2014: Jarden Reports Record Net Sales in 2Q

Jul 29, 2014: LG USA Names VanderWaal to Head Marketing

Jul 29, 2014: Smart Meters May Provide An Entrance Point for Cyber Attacks on the Connected Home

Jul 29, 2014: TCL Will Manufacture Portable HVAC Equipment for Soleus Air

Jul 29, 2014: HVACR Contractors Outlook Remains Positive

More Daily News>>

RSS Feeds
.........................................................
Appliance Industry
Market Research

...........................................................

March 2014: Market Research - 62nd Annual U.S. Appliance Industry Forecast
February 2014: Appliance Magazine Market Insight: December 2013
January 2014: Market Research - Appliance Historical Statistical Review: 1954-2012
January 2014: Appliance Magazine Market Insight: November 2013




 
Contact Us | About Us | Subscriptions | Advertising | Home
UBM Canon © 2014  

Please visit these other UBM Canon sites

UBM Canon Corporate | Design News | Test & Measurement World | Packaging Digest | EDN | Qmed | Pharmalive | Plastics Today | Powder Bulk Solids | Canon Trade Shows